Recombinant IL4 (Pascolizumab Biosimilar) 抗体
This anti-IL4 (Pascolizumab Biosimilar) antibody is a Human 单克隆 antibody detecting IL4 (Pascolizumab Biosimilar) in ELISA, Func, BR 和 InhA. Suitable for 人.
产品编号 ABIN7543170
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant IL4 (Pascolizumab Biosimilar) 抗体 (ABIN7543170)
抗原
IL4 (Pascolizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Human
克隆类型
单克隆
标记
This IL4 (Pascolizumab Biosimilar) antibody is un-conjugated
应用范围
ELISA, Functional Studies (Func), Blocking Reagent (BR), Inhibition Assay (InhA)
克隆位点
SB240683
-
-
原理
- Anti-IL-4 [SB240683 (Pascolizumab, humanized 3B9)], Human IgG1, kappa
-
特异性
- This antibody binds human and cynomolgus monkey IL-4 and does not cross react with IL-4 from mouse, rat, cow, goat or horse. It does show binding to glycosylated interleukin-4. Interleukin-4 is a receptor for both interleukin 4 and interleukin 13. It couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.
-
交叉反应
- Cynomolgus
-
产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
纯化方法
- Protein A affinity purified
-
免疫原
- The original mouse antibody was generated by immunizing F1 hybrids of Balb/c and C57BL/6 mice with recombinant human IL-4 in Freunds complete adjuvant. The humanized version was generated by grafting CDRs of murine parent antibody onto human IgG1 kappa heavy- and light-chain frameworks.
-
亚型
- IgG1 kappa
-
-
-
-
应用备注
- The original mouse version of this antibody can recognize recombinant human IL-4 in an ELISA and is also capable of inhibiting IL-4 dependent T-cell proliferation in vitro (PMID: 7517357). Binding of this humanized antibody completely blocks the binding of IL-4 to IL-4R. An in vitro study demonstrated that pascolizumab effectively neutralized IL-4 bioactivity in human cell lines including inhibited the proliferation of human T cells, human B cells and TF-1 cells, inhibition of interleukin-4-dependent IgE production by human PBMCs and up-regulation of Fc RII. It also inhibited the early events of asthma including TH2 cell differentiation, eosinophilia and IgE up-regulation. In vivo pharmacokinetic and chronic safety testing in cynomolgus monkeys demonstrated that pascolizumab was well tolerated without inducing adverse clinical responses (PMID:12296858). The pharmacokinetics of the human version of this antibody in the male Sprague Dawley rat was studied and the half life of the antibody was determined to be 11 days (US5914110A). A Phase I trial with a single intravenous dose in mild to moderate asthma demonstrated that it was well tolerated and had an elimination half-life of more than 2 weeks (Shames et al., 2001). However, a subsequent large-scale, multidose phase II trial in steroid-naive subjects with asthma was terminated because preliminary data showed that pascolizumab did not provide clinical benefit (clinical trials: NCT00024544).
-
限制
- 仅限研究用
-
-
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- IL4 (Pascolizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- IL4, BSF-1, Interleukin-4, B-cell stimulatory factor 1, Binetrakin, Lymphocyte stimulatory factor 1, Pitrakinra
-
UniProt
- P05112
抗原
-
You are here:
